The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier
- 29 June 2023
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (13) , 12513-12534
Abstract
Although significant advances have been made in the diagnosis and treatment of breast cancer (BC) in recent years, BC remains the most common cancer in women and one of the main causes of death among women worldwide. Currently, more than half of BC patients have no known risk factors, emphasizing the significance of identifying more tumor-related factors. Therefore, we urgently need to find new therapeutic strategies to improve prognosis. Increasing evidence demonstrates that the microbiota is present in a wider range of cancers beyond colorectal cancer. BC and breast tissues also have different types of microbiotas that play a key role in carcinogenesis and in modulating the efficacy of anticancer treatment, for instance, chemotherapy, radiotherapy, and immunotherapy. In recent years, studies have confirmed that the microbiota can be an important factor directly and/or indirectly affecting the occurrence, metastasis and treatment of BC by regulating different biological processes, such as estrogen metabolism, DNA damage, and bacterial metabolite production. Here, we review the different microbiota-focused studies associated with BC and explore the mechanisms of action of the microbiota in BC initiation and metastasis and its application in various therapeutic strategies. We found that the microbiota has vital clinical value in the diagnosis and treatment of BC and could be used as a biomarker for prognosis prediction. Therefore, modulation of the gut microbiota and its metabolites might be a potential target for prevention or therapy in BC.Keywords
Funding Information
- Beijing Medical Award Foundation (No. YXJL-2020-1225-0323)
- Heilongjiang Natural Science Foundation of China (No. LH2020H120)
- Haiyan Research Fund of Harbin Medical University Cancer Hospital (No. JJZD2020-04)
- Beijing MDK Public Welfare Foundation Research Fund (No. MDK-2022-1001)
- Postdoctoral Scientific Research Developmental Fund of Heilongjiang (No. LBH-Q22)
This publication has 127 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- High Prevalence of Mucosa-Associated E. coli Producing Cyclomodulin and Genotoxin in Colon CancerPLOS ONE, 2013
- Association of Fecal Microbial Diversity and Taxonomy with Selected Enzymatic FunctionsPLOS ONE, 2012
- Microbiome and MalignancyCell Host & Microbe, 2011
- Characterization of the Diversity and Temporal Stability of Bacterial Communities in Human MilkPLOS ONE, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The NIH Human Microbiome ProjectGenome Research, 2009
- Human gut microbiota in obesity and after gastric bypassProceedings of the National Academy of Sciences of the United States of America, 2009
- Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort studyBMJ, 2007
- Human gut microbes associated with obesityNature, 2006